Retatrutide is an unlicensed investigational triple incretin receptor agonist by Eli Lilly
Unlike full-length HGH, AOD-9604 does not significantly impact blood sugar levels or cause IGF-1 elevation, making it a safer alternative for fat loss
It was found through preliminary research that treatment with AOD9604 over the course of 14 days in obese mice led to decreased body weight and body fat and was shown to increase the activity of the beta(3)-adrenergic receptors in the fat cells to the same level as those in lean mice
Specifically, it produces no IGF-1 elevation (avoiding proliferative concerns), no negative impact on glucose metabolism (avoiding diabetes risk), no fluid retention or edema, and no concerning patterns of joint pain that can occur with growth hormone
Google Review I went in for a consultation and left a patient
Wait 10-15 seconds after swabbing before inserting the needle